Required S1318 Training

All copyright and other intellectual property rights subsisting in this S1318 Manual, including without limitation all text, images, graphics and code contained in the course, and in its look and feel ("Contents") are owned by Group. Except where otherwise specified, you may view, copy and print the Contents only for your own use for this Course and related to the performance of duties stemming from this Course. The Group reserves the right, but has no obligation, to change the Contents at any time.

Other than as specified above, neither the Manual nor any of its Contents may be modified or copied in whole or part in any form, including by framing, incorporation into other websites or other publication, or be used to create any derivative work. No links to the Course website may be included in any other website without the Group's prior written permission. Other than as specified above, nothing in this Course should be construed as granting any right or license. None of the Contents may be changed, nor may any copyright or author attribution notice appearing on any of the Contents be altered or removed, without the Group's prior permission.

Training Slides

Each institution is required to have at least one person read the S1318 Manual for Blinatumomab Outpatient Administration before enrolling patients to the S1318 study. To obtain credit for completing the training, please complete the short form at the bottom of this page, once you have read through the manual. A training confirmation will then be displayed. This page serves as acknowledgement from SWOG that your site has completed the required training. Please print the confirmation page so you can upload it via CTSU Regulatory Submission Portal and receive credit for completing the training.

S1318 Manual for Blinatumomab Outpatient Administration

By entering my information below, I am certifying the following:

• I have read and understand the blinatumomab outpatient administration information (available from the link above).

• I have provided the blinatumomab outpatient administration information (available from the link above) to the participating outpatient administration facility or home health organization, and clarified any/all outstanding questions in this regard.

• We have developed and implemented a plan to ensure that our site receives (from the outpatient administration facility or home health organization) all protocol-required documentation for blinatumomab drug-accountability, infusion rates and any adverse reactions that the patient may experience while receiving blinatumomab in the outpatient setting (and that this information is, in turn, maintained at the SWOG/NCTN site and/or submitted to SWOG/CTSU in accordance with the protocol).

• We have provided the outpatient administration facility or home health information with both a central point of contact for ongoing communication with our site and also my emergency contact information and emergency contact information for our site (in the event that the site is unable to reach me directly). We have received at least two primary points of contact for the outpatient administration facility or home health organization who will be responsible for clarifying any questions that may arise during the course of patient treatment and for the duration that the protocol remains active.